No profile data available.
Spyre Therapeutics, Inc. (SYRE) is a healthcare company in the digestive system treatment drugs industry, based in Waltham, United States, with about 125 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$155.20 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $7.91 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases.
Spyre Therapeutics reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$7.91 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (digestive system treatment drugs) include Abivax Société Anonyme (ABVX), Ironwood Pharmaceuticals, Inc. (IRWD), Phathom Pharmaceuticals, Inc. (PHAT), Palisade Bio, Inc. (PALI).